Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00810017 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer
A Phase 2 study, sponsored by Medstar Health Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00810017 is a Phase 2 study that was terminated before completion, run by Medstar Health Research Institute. The registered enrollment target is 2 participants.
The verdict
NCT00810017, a Phase 2 study, was terminated before completion, sponsored by Medstar Health Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study is for women and men who have previously treated metastatic (has spread to other parts in the body), Her2- positive breast cancer. The purpose of this study is to find out what effects (good and bad) the FDA-approved drugs etoposide and trastuzumab have on this type of breast cancer and to determine if these drugs are safe to use together. This research is being done to find more effective treatment for this type of condition. In this study, trastuzumab and etoposide will be given by intravenous infusion (IV; through a vein) on the first 3 days of every 3-week cycle. This is repeated for 6 cycles. After 6 cycles, only trastuzumab will be given until worsening of disease. In this study, a small amount of your tissue that was collected when you had surgery will be evaluated in the lab to look at genetic differences among people and how those differences may affect a response to a specific drug or medicine. This testing will look for a gene called Top2A. Previous studies suggest that people who have both the Top2A and Her2 genes respond to certain chemotherapies (anti-cancer drugs) differently from those who only have the Her2 gene.
Interventions
- DRUG Trastuzumab
- DRUG Etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00810017
The ClinicalTrials.gov registry entry for NCT00810017 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trastuzumab is the first listed.
NCT00810017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00810017 about?
NCT00810017 is a clinical study titled "Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer". This study is for women and men who have previously treated metastatic (has spread to other parts in the body), Her2- positive breast cancer. The purpose of this study is to find out what effects (good and bad) the FDA-approved drugs etoposide and trastuzumab have on this type of breast cancer and t...
What is the current status of trial NCT00810017?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2009-02. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00810017?
The interventions under investigation include: Trastuzumab (DRUG), Etoposide (DRUG).
Who is sponsoring clinical trial NCT00810017?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.